

Bakers Union and FELRA Health and Welfare fund

Quarterly Review
January - March 2020

June 17, 2020

Agenda: 1Q2020 Quarterly Review

Agenda

1. Key Discussion Topics

2. Performance Summary

3. Trend

4. Top Disease States

Your OptumRx Team



Holly Agoney

Strategic Account Executive



Nicole Rogers

Pharmacy Account Manager



Fabian Gonzalez

Pharmacy Service Specialist



Adam Towner

Director, Client Management

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,600 Individual / \$5,000 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,600 Individual / \$3,200 Family

Co-pays

Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Select Formulary

☐ Effective 7/1/19


- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = -0.8% Specialty trend = -0.8%
- ❑ Specialty accounted for 0.8% of claims
- ❑ Top 5 disease states accounted for 70% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions
- ❑ UM Outcome Savings = \$106,900
 - ❑ This is for all PA, ST, QL currently in place

Key Statistics - Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union has experience period over period.

- Eligibility has decreased by -30.
- Number of utilizers has decreased by -19.

Total Rx
CURRENT
2,202
PREVIOUS
2,226
PERCENT CHANGE
-1.1%

Total plan paid
CURRENT
\$270,767
PREVIOUS
\$284,432
PERCENT CHANGE
-4.8%

Utilizers
CURRENT
338
PREVIOUS
357
PERCENT CHANGE
-5.3%

Key Statistics with Benchmark Comparison

Your benchmark comparison

LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -0.8%, compared to the benchmark trend of 4.4%
- Member Paid Share changed by 1.3% period over period, compared to the benchmark of 2.0%

Key statistics	Current	Previous	Percent change	Benchmark	
				Current	Percent change
Average age	41.3	41.0	0.7%	38.5	-1.0%
Plan paid PMPM	\$127.78	\$128.76	-0.8%	\$89.28	4.4%
Plan paid per Rx	\$122.96	\$127.78	-3.8%	\$119.08	1.7%
Rxs PMPM	1.04	1.01	3.1%	0.75	2.7%
Average days supply	26.5	26.2	1.3%	39.2	5.2%
Days supply PMPM	27.6	26.4	4.5%	29.4	8.0%
Member paid share	7.9%	7.8%	1.3%	9.4%	2.0%
Member paid per Rx	\$11.85	\$12.42	-4.6%	\$9.51	6.2%
Generic dispensing rate	85.0%	85.3%	-0.4%	86.9%	1.0%
Home delivery rate	1.1%	1.1%	0.0%	8.4%	-2.1%
Retail 90 rate	0.2%	0.2%	0.0%	15.4%	17.6%
Percent of specialty plan paid	40.8%	40.8%	0.0%	33.6%	16.5%

Key Specialty Statistics

Client totals



The key metrics here help highlight the changes Bakers Union has experience period over period.

- Eligibility has decreased by -30.
- Number of utilizers was unchanged.

Total Rx's

CURRENT

18

PREVIOUS

17

PERCENT CHANGE

5.9%

Total plan paid

CURRENT

\$110,420

PREVIOUS

\$116,028

PERCENT CHANGE

-4.8%

Utilizers

CURRENT

8

PREVIOUS

8

PERCENT CHANGE

0.0%

Key Specialty Statistics with Benchmark Comparison

Your benchmark comparison

LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -0.8%, compared to the benchmark trend of 21.7%
- Member Paid Share changed by -86.7% period over period, compared to the benchmark of -6.9%

Key statistics				Benchmark	
	Current	Previous	Percent change	Current	Percent change
Average age	41.3	41.0	0.7%	38.5	-1.0%
Plan paid PMPM	\$52.11	\$52.52	-0.8%	\$29.99	21.7%
Plan paid per Rx	\$6,134.47	\$6,825.16	-10.1%	\$5,061.49	4.1%
Rxs PMPM	0.01	0.01	0.0%	0.01	16.9%
Average days supply	28.9	29.3	-1.4%	31.6	1.3%
Days supply PMPM	0.2	0.2	8.9%	0.2	18.3%
Member paid share	0.2%	1.5%	-86.7%	3.5%	-6.9%
Member paid per Rx	\$15.58	\$105.80	-85.3%	\$174.64	12.4%
Generic dispensing rate	0.0%	0.0%	0.0%	33.0%	-7.0%
Home delivery rate	0.0%	0.0%	0.0%	1.1%	-13.9%
Retail 90 rate	0.0%	0.0%	0.0%	5.1%	11.4%

Trend Summary


Your benchmark comparison

LABOR AND TRUST ▼

Trend

Plan paid PMPM has decreased -0.8% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 0.8% of claims.



-5.2% under benchmark



+1.8% over benchmark




-22.5% under benchmark

Total Trend Components


Your benchmark comparison

LABOR AND TRUST ▼




Traditional vs. Specialty Trend Components

Traditional Trend: -0.7%



Specialty Trend: -0.8%



Top Disease States

Top 5 disease states account for 70% of total Plan Paid

- Inflammatory Conditions accounts for 35.9% of total plan paid, with trend driven by Utilization. HUMIRA PEN was the top drug
- Diabetes accounts for 16.9% of total plan paid, with trend driven by Cost. HUMALOG MIX 50/50 KWIKPEN was the top drug

Inflammatory Conditions ▲ PMPM \$45.93 Trend 32.6%	Diabetes ▲ PMPM \$21.65 Trend 36.6%	Cardiovascular ▲ PMPM \$7.32 Trend 83.6%
HIV ▲ PMPM \$7.18 Trend 52.8%	Asthma / COPD ▲ PMPM \$7.16 Trend 82.6%	All other ▼ PMPM \$38.54 Trend -41.3%

Top 20 Drugs

Curr	Prev	Drug name	Therapy class	Utilizers	Total plan paid	Curr PMPM	BOB PMPM	% Trend	Utilization	Drug mix	Cost	Mbr contrb
1	10	HUMIRA PEN	Chronic Inflammatory Disease	2	\$34,519	\$16.29	\$3.88	570.0%	525.5%	0.0%	44.8%	-0.3%
2	2	TREMFYA	Chronic Inflammatory Disease	1	\$23,067	\$10.89	\$0.34	6.8%	4.2%	0.0%	2.6%	0.0%
3	4	SIMPONI ARIA	Chronic Inflammatory Disease	1	\$15,244	\$7.19	\$0.01	6.8%	4.2%	0.0%	2.6%	0.0%
4	5	OTEZLA	Chronic Inflammatory Disease	2	\$14,652	\$6.91	\$0.70	8.7%	4.2%	0.0%	4.5%	0.0%
5	1	IBRANCE	Oncology	1	\$13,132	\$6.20	\$0.61	-62.9%	-65.3%	0.0%	2.3%	0.0%
6	8	STRIBILD	HIV-Multiclass Combo	1	\$9,979	\$4.71	\$0.08	17.5%	4.2%	0.0%	13.1%	0.1%
7		DUPIXENT	Chronic Inflammatory Disease	1	\$9,808	\$4.63	\$0.58	0.0%	0.0%	0.0%	0.0%	0.0%
8	11	HUMALOG MIX 50/ 50 KWIKPEN	Insulin	2	\$6,375	\$3.01	\$0.01	34.6%	28.6%	4.9%	1.4%	-0.2%
9		TRUVADA	HIV-Multiclass Combo	1	\$4,643	\$2.19	\$0.58	0.0%	0.0%	0.0%	0.0%	0.0%
10	13	JANUVIA	DPP-4 Inhibitors & Combos	5	\$4,603	\$2.17	\$1.31	11.1%	6.0%	0.0%	5.2%	-0.1%
11	12	ABSORICA	Acne Products	1	\$4,492	\$2.12	\$0.06	4.9%	4.2%	0.0%	0.0%	0.7%
12	32	HUMULIN R U-500 (CONCENTRATED)	Insulin	1	\$4,365	\$2.06	\$0.04	212.7%	212.7%	0.0%	0.0%	0.0%
13	115	LANTUS	Insulin	1	\$4,132	\$1.95	\$0.28	1,436.7%	160.6%	0.0%	1,267.3%	8.7%
14	16	VICTOZA	GLP-1 Receptor Agonists	2	\$3,769	\$1.78	\$0.78	9.5%	4.2%	0.0%	5.2%	0.1%
15	41	BREO ELLIPTA	Inhaled Asthma/COPD Combo	4	\$3,649	\$1.72	\$0.59	204.0%	186.7%	1.2%	14.4%	1.7%
16	21	SYMBICORT	Inhaled Asthma/COPD Combo	6	\$3,587	\$1.69	\$0.80	62.5%	63.8%	0.0%	-1.3%	0.0%
17	17	JARDIANCE	SGLT-2 Inhibitors & Combos	2	\$3,013	\$1.42	\$1.30	10.7%	4.2%	0.0%	6.3%	0.2%
18		BYDUREON BCISE	GLP-1 Receptor Agonists	1	\$2,792	\$1.32	\$0.17	0.0%	0.0%	0.0%	0.0%	0.0%
19	37	JANUMET XR	DPP-4 Inhibitors & Combos	2	\$2,723	\$1.29	\$0.23	119.1%	108.5%	0.0%	10.4%	0.2%
20	20	REXULTI	Atypical Antipsychotics	1	\$2,591	\$1.22	\$0.16	4.8%	4.2%	0.0%	4.8%	-4.3%

Top 20 Traditional Drugs

Curr	Prev	Drug name	Therapy class	Utilizers	Total plan paid	Curr PMPM	BOB PMPM	% Trend	Utilization	Drug mix	Cost	Mbr contrb
1	2	STRIBILD	HIV-Multiclass Combo	1	\$9,979	\$4.71	\$0.08	17.5%	4.2%	0.0%	13.1%	0.1%
2	4	HUMALOG MIX 50/ 50 KWIKPEN	Insulin	2	\$6,375	\$3.01	\$0.01	34.6%	28.6%	4.9%	1.4%	-0.2%
3		TRUVADA	HIV-Multiclass Combo	1	\$4,643	\$2.19	\$0.58	0.0%	0.0%	0.0%	0.0%	0.0%
4	6	JANUVIA	DPP-4 Inhibitors & Combos	5	\$4,603	\$2.17	\$1.31	11.1%	6.0%	0.0%	5.2%	-0.1%
5	5	ABSORICA	Acne Products	1	\$4,492	\$2.12	\$0.06	4.9%	4.2%	0.0%	0.0%	0.7%
6	25	HUMULIN R U-500 (CONCENTRATED)	Insulin	1	\$4,365	\$2.06	\$0.04	212.7%	212.7%	0.0%	0.0%	0.0%
7	106	LANTUS	Insulin	1	\$4,132	\$1.95	\$0.28	1,436.7%	160.6%	0.0%	1,267.3%	8.7%
8	9	VICTOZA	GLP-1 Receptor Agonists	2	\$3,769	\$1.78	\$0.78	9.5%	4.2%	0.0%	5.2%	0.1%
9	33	BREO ELLIPTA	Inhaled Asthma/COPD Combo	4	\$3,649	\$1.72	\$0.59	204.0%	186.7%	1.2%	14.4%	1.7%
10	14	SYMBICORT	Inhaled Asthma/COPD Combo	6	\$3,587	\$1.69	\$0.80	62.5%	63.8%	0.0%	-1.3%	0.0%
11	10	JARDIANCE	SGLT-2 Inhibitors & Combos	2	\$3,013	\$1.42	\$1.30	10.7%	4.2%	0.0%	6.3%	0.2%
12		BYDUREON BCISE	GLP-1 Receptor Agonists	1	\$2,792	\$1.32	\$0.17	0.0%	0.0%	0.0%	0.0%	0.0%
13	29	JANUMET XR	DPP-4 Inhibitors & Combos	2	\$2,723	\$1.29	\$0.23	119.1%	108.5%	0.0%	10.4%	0.2%
14	13	REXULTI	Atypical Antipsychotics	1	\$2,591	\$1.22	\$0.16	4.8%	4.2%	0.0%	4.8%	-4.3%
15	27	INVOKANA	SGLT-2 Inhibitors & Combos	2	\$2,444	\$1.15	\$0.52	79.0%	73.7%	0.0%	5.2%	0.1%
16	18	DEXILANT	Proton Pump Inhibitors	3	\$2,399	\$1.13	\$0.34	22.5%	17.3%	0.0%	3.5%	1.8%
17		ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	\$2,062	\$0.97	\$0.40	0.0%	0.0%	0.0%	0.0%	0.0%
18	32	ELIQUIS	Oral Anticoagulants	2	\$1,914	\$0.90	\$1.75	56.5%	39.0%	0.0%	17.1%	0.4%
19	15	LANTUS SOLOSTAR	Insulin	3	\$1,850	\$0.87	\$0.99	-15.3%	-31.8%	0.0%	14.2%	2.3%
20	12	JANUMET	DPP-4 Inhibitors & Combos	2	\$1,815	\$0.86	\$0.40	-27.0%	-30.5%	0.0%	3.4%	0.2%

Top 20 Specialty Drugs

Curr	Prev	Drug name	Therapy class	Utilizers	Total plan paid	Curr PMPM	BOB PMPM	% Trend	Utilization	Drug mix	Cost	Mbr contrb
1	7	HUMIRA PEN	Chronic Inflammatory Disease	2	\$34,519	\$16.29	\$3.88	570.0%	525.5%	0.0%	44.8%	-0.3%
2	2	TREMFYA	Chronic Inflammatory Disease	1	\$23,067	\$10.89	\$0.34	6.8%	4.2%	0.0%	2.6%	0.0%
3	3	SIMPONI ARIA	Chronic Inflammatory Disease	1	\$15,244	\$7.19	\$0.01	6.8%	4.2%	0.0%	2.6%	0.0%
4	4	OTEZLA	Chronic Inflammatory Disease	2	\$14,652	\$6.91	\$0.70	8.7%	4.2%	0.0%	4.5%	0.0%
5	1	IBRANCE	Oncology	1	\$13,132	\$6.20	\$0.61	-62.9%	-65.3%	0.0%	2.3%	0.0%
6		DUPIXENT	Chronic Inflammatory Disease	1	\$9,808	\$4.63	\$0.58	0.0%	0.0%	0.0%	0.0%	0.0%